Biophan Announces Availability of Corporate Video Reporting on Vanguard Research in Drug Elution and MRI Applications; Video Describes Company's Advanced Product Initiatives on Leading Edge of Multi-Billion-Dollar Biotechnology Markets.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH - News), a developer of next-generation biomedical technology, has announced the availability of a new online video that offers an update on the Company's product development initiatives in the fast-growing multi-billion-dollar markets involving applications of drug-delivery and advanced Magnetic Resonance Imaging (MRI) technologies.

"The technologies we discuss in this video demonstrate some of the critical biomedical markets that Biophan continues to innovate within," said Michael Weiner, CEO of Biophan. "Our rich intellectual property portfolio includes a commanding set of technology solutions in the still-growing, $40 billion-plus market for next-generation drug delivery systems, a technology also known as drug-elution. Biophan holds dozens of patents or patent applications in nanotechnology, advanced implantable miniature biomedical motors, and other scientific fields that have the potential to play a significant role in this important area of next-generation health care.

"Additionally, the video goes into some detail about our new BiophanEurope division," continued Mr. Weiner. "That division, which contains a recently-acquired company in Germany formerly called AMRIS, is developing advanced solutions that allow active MRI imaging applications that make cardiovascular stents and vena cava filters safe and effective to use within MRI systems. Vena cava filters capture blood clots that can cause death or serious health complications, but under current technology, there is no effective imaging technology that can enable doctors to see inside the filters to determine if any clots have been captured. The MRI-based solutions we're developing at BiophanEurope appear to be the first and only technology that can enable accurate imaging of the inside of stents and vena cava filters."

Biophan invites all interested parties and investors to view the video by visiting http://www.trilogy-capital.com/tcp/biophan/video.html.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.